A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT ID: NCT00002305

Last Updated: 2005-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningitis, Cryptococcal HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flucytosine

Intervention Type DRUG

Fluconazole

Intervention Type DRUG

Amphotericin B

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Concurrent Medication:

Allowed:

* Immunosuppressant therapy.
* Antiviral therapy such as zidovudine.
* Prophylaxis for Pneumocystis carinii pneumonia.

Concurrent Treatment:

Allowed:

* Radiation therapy for mucocutaneous Kaposi's sarcoma.

Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.

* No prior systemic antifungal therapy for cryptococcosis.
* Relapse after prior therapy.
* Success of prior therapy must have been documented by negative cerebrospinal fluid (CSF) culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into study.

Prior Medication:

Allowed:

* Immunosuppressant therapy.
* Antiviral therapy (such as zidovudine).
* Prophylaxis for Pneumocystis carinii pneumonia.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

* Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
* History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.
* Moderate or severe liver disease.
* Comatose.
* Unlikely to survive more than 2 weeks.
* Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.

Concurrent Medication:

Excluded:

* Coumadin-type anticoagulants.
* Oral hypoglycemics.
* Barbiturates.
* Phenytoin.
* Immunostimulants.
* Investigational drugs or approved (licensed) drugs for investigational indications.
* Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.
* Excluded within 4 weeks of study entry:
* Greater than 1 mg/kg/wk amphotericin B.

Concurrent Treatment:

Excluded:

* Lymphocyte replacement.

Patients with the following are excluded:

* Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
* History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.
* Moderate or severe liver disease.
* Comatose.
* Unlikely to survive more than 2 weeks.

Prior Medication:

Excluded:

* Coumadin-type anticoagulants.
* Oral hypoglycemics.
* Barbiturates.
* Phenytoin.
* Immunostimulants.
* Investigational drugs or approved (licensed) drugs for investigational indications.
* Excluded within 4 weeks of study entry:
* Greater than 1 mg/kg/wk amphotericin B.

Prior Treatment:

Excluded:

* Lymphocyte replacement.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univ of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Tucson Veterans Administration Med Ctr

Tucson, Arizona, United States

Site Status

UCLA CARE Ctr

Los Angeles, California, United States

Site Status

Dr Shelly Gordon

San Francisco, California, United States

Site Status

Dr Martin Mass

San Francisco, California, United States

Site Status

Dr Paul Rothman

Sherman Oaks, California, United States

Site Status

Christiana Hosp / Med Ctr of Delaware

Wilmington, Delaware, United States

Site Status

George Washington Univ Med Ctr

Washington D.C., District of Columbia, United States

Site Status

Univ of Miami School of Medicine

Miami, Florida, United States

Site Status

Univ of South Florida

Tampa, Florida, United States

Site Status

Emory Univ School of Medicine

Atlanta, Georgia, United States

Site Status

Med College of Georgia

Augusta, Georgia, United States

Site Status

DeKalb Gen Hosp

Decatur, Georgia, United States

Site Status

Northwestern Univ Med School

Chicago, Illinois, United States

Site Status

Louisiana State Univ School of Medicine

New Orleans, Louisiana, United States

Site Status

Tulane Univ School of Medicine

New Orleans, Louisiana, United States

Site Status

Dr Michael Bach

Portland, Maine, United States

Site Status

Univ of Maryland / Inst of Human Virology

Baltimore, Maryland, United States

Site Status

Loch Raven Veterans Hosp

Baltimore, Maryland, United States

Site Status

New England Med Ctr

Boston, Massachusetts, United States

Site Status

Univ Hosp

Boston, Massachusetts, United States

Site Status

Ann Arbor Veterans Administration Med Ctr

Ann Arbor, Michigan, United States

Site Status

Harper Hosp

Detroit, Michigan, United States

Site Status

Henry Ford Hosp

Detroit, Michigan, United States

Site Status

Washington Univ School of Medicine

St Louis, Missouri, United States

Site Status

Albany Med College / AIDS Treatment Ctr

Albany, New York, United States

Site Status

Jewish Hosp Ctr Affiliation

Jamaica, New York, United States

Site Status

Chelsea Village Med Ctr

New York, New York, United States

Site Status

Mem Sloan - Kettering Cancer Ctr

New York, New York, United States

Site Status

Saint Luke's - Roosevelt Hosp Ctr

New York, New York, United States

Site Status

Columbia Univ

New York, New York, United States

Site Status

Harlem AIDS Treatment Group / Harlem Hosp Ctr

New York, New York, United States

Site Status

Montefiore Med Ctr / Bronx Municipal Hosp

The Bronx, New York, United States

Site Status

Bronx Veterans Administration / Mount Sinai Hosp

The Bronx, New York, United States

Site Status

Univ of North Carolina School of Medicine

Chapel Hill, North Carolina, United States

Site Status

Cincinnati Veterans Adm Med Ctr / Univ Hosp

Cincinnati, Ohio, United States

Site Status

Ohio State Univ Hosp

Columbus, Ohio, United States

Site Status

Univ of Tennessee

Memphis, Tennessee, United States

Site Status

Dr Daniel Barbaro

Dallas, Texas, United States

Site Status

Univ TX Galveston Med Branch

Galveston, Texas, United States

Site Status

United States Air Force Med Ctr

Lackland Air Force Base, Texas, United States

Site Status

Univ TX San Antonio Health Science Ctr

San Antonio, Texas, United States

Site Status

Richmond AIDS Consortium

Richmond, Virginia, United States

Site Status

CHG-118 Group Health / Cooperative of Puget Sound

Seattle, Washington, United States

Site Status

Saint Michael's Hosp

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

056-159

Identifier Type: -

Identifier Source: secondary_id

012F

Identifier Type: -

Identifier Source: org_study_id